Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1807MR)

This product GTTS-WQ1807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3992MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ2651MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ3612MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ4013MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ15673MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ12466MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12646MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ7764MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW